SOMA Platform
Pancreatic Cancer
Key Facts
About Coherence Neuro
Coherence Neuro is a private, clinical-stage biotech founded in 2022, operating at the convergence of neurotechnology, neurobiology, and AI to treat cancer. The company's mission is to improve the length and quality of life for cancer patients by introducing a 'fourth pillar' of cancer therapy—bioelectronic modulation—alongside drugs, radiation, and surgery. Their lead program, SOMA, targets high-grade gliomas and has initiated its first safety study, with pipeline expansion into pancreatic cancer underway. Backed by a team of experts from Cambridge, Philips, Siemens, and Abbott, Coherence is building a platform with potential applications across numerous diseases influenced by the body's bioelectric code.
View full company profileAbout Coherence Neuro
Coherence Neuro is a private, clinical-stage biotech founded in 2022, operating at the convergence of neurotechnology, neurobiology, and AI to treat cancer. The company's mission is to improve the length and quality of life for cancer patients by introducing a 'fourth pillar' of cancer therapy—bioelectronic modulation—alongside drugs, radiation, and surgery. Their lead program, SOMA, targets high-grade gliomas and has initiated its first safety study, with pipeline expansion into pancreatic cancer underway. Backed by a team of experts from Cambridge, Philips, Siemens, and Abbott, Coherence is building a platform with potential applications across numerous diseases influenced by the body's bioelectric code.
View full company profileOther Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Ampligen® (rintatolimod) | AIM ImmunoTech | Early Access Program |
| HBM9027 | Harbour BioMed | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| AHPBA IRE Registry | AngioDynamics | Post-Market Registry |
| SIMBs + Immunotherapy | Advanced Microbubbles | Pre-clinical |
| CLS-014 | CLS Therapeutics | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Pritumumab (PTB) | Nascent Biotech | Phase II (Planned) |
| Pancreatic Cancer Test | Mosaique Diagnostic | Development |
| Iontophoretic System | Continuity Biosciences | Pre-clinical |
| Lixumistat (IM156) | ImmunoMet Therapeutics | Phase 1b |
| Electron IORT | Intraop Medical | Approved |